These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

335 related items for PubMed ID: 22646219

  • 1. Effect of desvenlafaxine on mood and climacteric symptoms in menopausal women with moderate to severe vasomotor symptoms.
    Cheng RJ, Dupont C, Archer DF, Bao W, Racketa J, Constantine G, Pickar JH.
    Climacteric; 2013 Feb; 16(1):17-27. PubMed ID: 22646219
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial.
    Speroff L, Gass M, Constantine G, Olivier S, Study 315 Investigators.
    Obstet Gynecol; 2008 Jan; 111(1):77-87. PubMed ID: 18165395
    [Abstract] [Full Text] [Related]

  • 3. Maintenance of the efficacy of desvenlafaxine in menopausal vasomotor symptoms: a 1-year randomized controlled trial.
    Pinkerton JV, Archer DF, Guico-Pabia CJ, Hwang E, Cheng RF.
    Menopause; 2013 Jan; 20(1):38-46. PubMed ID: 23266839
    [Abstract] [Full Text] [Related]

  • 4. Identifying meaningful differences in vasomotor symptoms among menopausal women.
    Wyrwich KW, Spratt DI, Gass M, Yu H, Bobula JD.
    Menopause; 2008 Jan; 15(4 Pt 1):698-705. PubMed ID: 18369313
    [Abstract] [Full Text] [Related]

  • 5. Desvenlafaxine compared with placebo for treatment of menopausal vasomotor symptoms: a 12-week, multicenter, parallel-group, randomized, double-blind, placebo-controlled efficacy trial.
    Pinkerton JV, Constantine G, Hwang E, Cheng RF, Study 3353 Investigators.
    Menopause; 2013 Jan; 20(1):28-37. PubMed ID: 23010882
    [Abstract] [Full Text] [Related]

  • 6. Randomized placebo- and active-controlled study of desvenlafaxine for menopausal vasomotor symptoms.
    Bouchard P, Panay N, de Villiers TJ, Vincendon P, Bao W, Cheng RJ, Constantine G.
    Climacteric; 2012 Feb; 15(1):12-20. PubMed ID: 22066790
    [Abstract] [Full Text] [Related]

  • 7. A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause.
    Archer DF, Seidman L, Constantine GD, Pickar JH, Olivier S.
    Am J Obstet Gynecol; 2009 Feb; 200(2):172.e1-10. PubMed ID: 19110224
    [Abstract] [Full Text] [Related]

  • 8. Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety.
    Archer DF, Dupont CM, Constantine GD, Pickar JH, Olivier S, Study 319 Investigators.
    Am J Obstet Gynecol; 2009 Mar; 200(3):238.e1-238.e10. PubMed ID: 19167693
    [Abstract] [Full Text] [Related]

  • 9. A pooled analysis of the efficacy of desvenlafaxine for the treatment of major depressive disorder in perimenopausal and postmenopausal women.
    Kornstein SG, Clayton AH, Bao W, Guico-Pabia CJ.
    J Womens Health (Larchmt); 2015 Apr; 24(4):281-90. PubMed ID: 25860107
    [Abstract] [Full Text] [Related]

  • 10. Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder.
    Kornstein SG, Jiang Q, Reddy S, Musgnung JJ, Guico-Pabia CJ.
    J Clin Psychiatry; 2010 Aug; 71(8):1088-96. PubMed ID: 20797382
    [Abstract] [Full Text] [Related]

  • 11. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA, Padmanabhan SK, Groark J, Brisard C, Farrington D.
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [Abstract] [Full Text] [Related]

  • 12. Post hoc analysis of the efficacy and safety of desvenlafaxine 50 mg/day in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder.
    Kornstein SG, Clayton A, Bao W, Guico-Pabia CJ.
    Menopause; 2014 Aug; 21(8):799-806. PubMed ID: 24448103
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of desvenlafaxine treatment for hot flashes associated with menopause: a meta-analysis of randomized controlled trials.
    Sun Z, Hao Y, Zhang M.
    Gynecol Obstet Invest; 2013 Aug; 75(4):255-62. PubMed ID: 23548358
    [Abstract] [Full Text] [Related]

  • 14. The effect of dose titration and dose tapering on the tolerability of desvenlafaxine in women with vasomotor symptoms associated with menopause.
    Gallagher JC, Strzinek RA, Cheng RF, Ausmanas MK, Astl D, Seljan P.
    J Womens Health (Larchmt); 2012 Feb; 21(2):188-98. PubMed ID: 22032759
    [Abstract] [Full Text] [Related]

  • 15. Bazedoxifene/conjugated estrogens and quality of life in postmenopausal women.
    Utian W, Yu H, Bobula J, Mirkin S, Olivier S, Pickar JH.
    Maturitas; 2009 Aug 20; 63(4):329-35. PubMed ID: 19647382
    [Abstract] [Full Text] [Related]

  • 16. The effect of a novel vaginal ring delivering oestradiol acetate on climacteric symptoms in postmenopausal women.
    Buckler H, Al-Azzawi F, UK VR Multicentre Trial Group.
    BJOG; 2003 Aug 20; 110(8):753-9. PubMed ID: 12892687
    [Abstract] [Full Text] [Related]

  • 17. Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy.
    Bachmann G, Bobula J, Mirkin S.
    Climacteric; 2010 Apr 20; 13(2):132-40. PubMed ID: 19863455
    [Abstract] [Full Text] [Related]

  • 18. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder.
    Arnold LM, Lu Y, Crofford LJ, Wohlreich M, Detke MJ, Iyengar S, Goldstein DJ.
    Arthritis Rheum; 2004 Sep 20; 50(9):2974-84. PubMed ID: 15457467
    [Abstract] [Full Text] [Related]

  • 19. [Non-hormonal treatment for vasomotor symptoms during menopause: role of desvenlafaxine].
    Lilue M, Palacios S.
    Ginecol Obstet Mex; 2009 Oct 20; 77(10):475-81. PubMed ID: 19902676
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of desvenlafaxine 50 mg compared with placebo in patients with moderate or severe major depressive disorder: a pooled analysis of six randomized, double-blind, placebo-controlled studies.
    Papakostas GI, Culpepper L, Fayyad RS, Musgnung J, Guico-Pabia CJ.
    Int Clin Psychopharmacol; 2013 Nov 20; 28(6):312-21. PubMed ID: 23881185
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.